Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community aflutter.
Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly's Verzenios, after new guidance from NICE backed use of the drug after surge
A survey of clinical research executives working in the cancer arena has found that nearly three quarters of them will include decentralised designs in trials due to start in the next 12 mo
A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick an
MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to HIBio.
Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken an option to buy the com